Scope
ASH provides a diagnostic pathway for suspected light-chain (AL) amyloidosis, distinguishing tests that raise suspicion from tissue confirmation and amyloid subtyping. Early diagnosis matters because cardiac, renal, neurological and other organ involvement may progress. The choice of surrogate or affected-organ biopsy depends on the presentation, expertise and access, with avoidance of diagnostic delay.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Use appropriate monoclonal-protein testing
- For suspected cardiac amyloidosis, test serum and urine immunofixation electrophoresis and serum free light chains with their ratio. Positivity in any one raises suspicion for AL; this strong recommendation has moderate-certainty evidence and does not mean that monoclonal protein alone confirms AL. [1]
- For unexplained proteinuria, consider the same serum/urine immunofixation and serum free-light-chain testing to raise suspicion of AL amyloidosis. This is conditional with low-certainty evidence; testing can also suggest other monoclonal-gammopathy-associated kidney diseases. [1]
- Do not use serum/urine protein electrophoresis alone as the screening or sole diagnostic tests for AL amyloidosis. Combine electrophoresis with immunofixation and serum free-light-chain testing; urine free-light-chain measurement is not recommended for detecting monoclonal protein. [1]
- Urine immunofixation can use a full-day collection or a random specimen, preferably the early-morning first void. A 24-hour collection is needed to assess proteinuria/albuminuria for renal involvement; interpret serum free light chains cautiously in renal impairment and autoimmune disease. [1]
- Interpret serum free-light-chain results using appropriate assay and renal-context reference ranges. Manufacturers and analytical platforms differ, and impaired kidney function substantially changes concentrations; a single universal laboratory interval is inappropriate. [1]
Choose the cardiac investigation by the preceding results
- When any monoclonal study is positive, cardiac biomarkers are abnormal AND echocardiography is nondiagnostic, consider cardiac MRI to increase suspicion of cardiac amyloidosis. The recommendation is conditional with moderate certainty; it is not a substitute for tissue confirmation of AL. [1]
- When any monoclonal study is positive, cardiac biomarkers are abnormal AND echocardiography is already consistent with amyloidosis, proceed to tissue biopsy rather than adding cardiac MRI. This conditional, very-low-certainty recommendation aims to avoid delay; high clinical suspicion warrants prompt tissue diagnosis. [1]
- When evaluating suspected cardiac amyloidosis, an abnormal cardiac biomarker means BNP, NT-proBNP or troponin above that laboratory’s reference range. Relevant echo findings include unexplained ventricular hypertrophy, reduced longitudinal strain with possible apical sparing, and worsening diastolic dysfunction; interpret the pattern clinically. [1]
Keep AL and ATTR imaging pathways distinct
- Do not use PYP, DPD or HMDP bone scintigraphy to diagnose cardiac AL amyloidosis. ASH strongly recommends against this use with moderate-certainty evidence; if a plasma-cell disorder is evident, do not delay appropriate tissue biopsy to obtain such a scan. [1]
- For suspected cardiac amyloidosis with normal serum free-light-chain testing AND no monoclonal proteins on serum AND urine immunofixation, use bone scintigraphy to diagnose cardiac ATTR. Include SPECT to confirm myocardial rather than blood-pool uptake; a single negative scan does not exclude ATTR when uncertainty persists. [1]
- In suspected or confirmed ATTR, assess family history and offer genetic counselling regardless of that history. Late-onset hereditary disease may have no recognized family history. [1]
Obtain and subtype diagnostic tissue without delay
- For suspected cardiac AL with abnormal biomarkers, diagnostic echocardiography AND a positive monoclonal study, either combined abdominal fat-pad sampling plus bone-marrow biopsy or endomyocardial biopsy is a conditional option. Choose according to clinical presentation, access and expertise; obtain tissue suitable for validated subtyping. [1]
- For suspected renal AL with a positive monoclonal study, conditionally start with BOTH fat-pad sampling and marrow biopsy rather than renal biopsy. A positive, appropriately subtyped surrogate sample may avoid renal biopsy; negative results from both require renal biopsy to evaluate amyloid or another cause. [1]
- In suspected renal amyloidosis, favour an upfront renal biopsy when another renal disorder is strongly suspected. If fat-pad amyloid cannot be subtyped, refer for renal biopsy. Do not delay an indicated target-organ biopsy while waiting for marrow results. [1]
- With monoclonal gammopathy and generalized small/large-fibre or autonomic neuropathy suspicious for AL, conditionally prefer combined fat-pad and marrow biopsy over nerve biopsy. If both are negative but suspicion remains high, obtain nerve or another affected-organ biopsy; another suspected nerve pathology may justify upfront nerve biopsy. [1]
- For suspected multiorgan AL, conditionally begin with combined fat-pad and marrow biopsies if they can be obtained promptly. Prefer symptomatic heart or kidney tissue if those biopsies are more feasible; negative surrogate samples with high suspicion require affected-organ biopsy. [1]
- Optimize fat-pad collection so the sample permits validated amyloid subtyping, and subtype all histologically proven amyloid promptly. Marrow biopsy should not be performed in isolation from immunological tests and cardiac biomarkers; these are coordinated diagnostic steps. [1]
- Historical pathology specimens from the preceding 3 years may be tested for amyloid, but this must not delay new diagnostic testing. For suspected gastrointestinal amyloid, obtain adequate deeper biopsies including submucosa; sampling technique and pathology expertise affect yield. [1]
Interpret positive tissue and define organ involvement
- In multiple myeloma or smouldering myeloma, consider Congo Red staining of marrow specimens already obtained. Do not perform a new marrow biopsy solely for staining in low-risk MGUS without clinical suspicion of systemic amyloidosis; the recommendation has very-low-certainty evidence. [1]
- A positive marrow Congo Red stain requires reassessment for systemic AL signs and symptoms and validated amyloid subtyping. Never start amyloid-directed therapy from marrow Congo Red positivity alone; seek expert pathology review when interpretation is difficult or results are discordant. [1]
- At confirmed AL diagnosis, assess major organ involvement even when cardiac symptoms are absent. ASH strongly recommends cardiac biomarkers, including troponin and BNP or NT-proBNP, together with cardiac imaging to establish the presence and extent of cardiac disease; evidence certainty is low. [1]
- For confirmed AL amyloidosis, include longitudinal-strain assessment on echocardiography; absence of apical sparing does not exclude involvement. Cardiac MRI may clarify early or nondiagnostic echo findings. Interpret biomarkers with renal function and pre-existing cardiac disease, using multidisciplinary expertise. [1]
Limitations and use
- This is diagnostic guidance, not an AL treatment regimen or a complete staging protocol. Many biopsy recommendations are conditional and based on low or very-low-certainty evidence. Free-light-chain assays and cardiac biomarker cutoffs vary with platform, renal function and clinical context; this summary does not provide universal numerical thresholds. Bone scintigraphy for ATTR has a distinct role and must not be used to establish AL amyloidosis. Local access and expert pathology/amyloid subtyping should guide the fastest reliable diagnostic route.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Diagnosis of light-chain amyloidosis
Selected recommendation material consulted
Publication details
- Issuing organisation
- ASH
- Resource type
- Clinical practice guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.